Literature DB >> 19635387

New highly sensitive enzyme immunoassay for the determination of pravastatin in human plasma.

Ibrahim A Darwish1, Abdul-Rahman M Al-Obaid, Hamoud A Al-Malaq.   

Abstract

New highly sensitive enzyme immunoassay (EIA) has been developed and validated for the determination of pravastatin (PRV) in human plasma samples. PRV was coupled to keyhole limpt hemocyanin (KLH) and bovine serum albumin (BSA) via its terminal carboxylic acid group by carbodiimide reagent. PRV-KLH conjugate was used as an immunogen for raising anti-PRV polyclonal antibody in rabbits. The generated anti-PRV antibody recognized PRV with high affinity and selectivity. PRV-BSA conjugate was immobilized onto microwell plates and used as a solid phase. The assay involved a competitive binding reaction between PRV, in plasma sample, and the immobilized PRV-BSA for the binding sites on a limited amount of the anti-PRV antibody. The anti-PRV antibody bound to the plate wells was quantified with horseradish peroxidase-labeled anti-immunoglobulin second anti-rabbit IgG antibody and 3,3',5,5'-tetramethylbenzidine as a substrate for the peroxidase enzyme. The concentration of PRV in the sample was quantified by its ability to inhibit the binding of the anti-PRV antibody to the immobilized PRV-BSA and subsequently the color development in the assay wells. The conditions of the proposed EIA were investigated and the optimum conditions were employed in the determination of PRV in plasma samples. The assay limit of detection was 0.2 ng mL(-1) and the effective working range at relative standard deviation (RSD) of <or=5% was 0.5-20 ng mL(-1). The mean analytical recovery of PRV from spiked plasma was 100.9+/-2.98%. The precision of the assay was satisfactory; RSD was 2.61-3.70 and 3.96-4.17% for intra- and inter-assay precision, respectively. The analytical procedure is convenient, and one can analyze approximately 200 samples per working day, facilitating the processing of large-number batch of samples. The proposed EIA has a great value in the routine analysis of PRV in plasma samples for its therapeutic monitoring and pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635387     DOI: 10.1016/j.talanta.2009.06.021

Source DB:  PubMed          Journal:  Talanta        ISSN: 0039-9140            Impact factor:   6.057


  4 in total

1.  Generation of polyclonal antibody with high avidity to rosuvastatin and its use in development of highly sensitive ELISA for determination of rosuvastatin in plasma.

Authors:  Ibrahim A Darwish; Abdul-Rahman M Al-Obaid; Hamoud A Al-Malaq
Journal:  Chem Cent J       Date:  2011-07-05       Impact factor: 4.215

2.  Synthesis of hapten, generation of specific polyclonal antibody and development of ELISA with high sensitivity for therapeutic monitoring of crizotinib.

Authors:  Mona M Al-Shehri; Adel S El-Azab; Manal A El-Gendy; Mohammed A Hamidaddin; Ibrahim A Darwish
Journal:  PLoS One       Date:  2019-02-11       Impact factor: 3.240

3.  Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir.

Authors:  Ibrahim A Darwish; Abdulrahman A Almehizia; Awwad A Radwan; Rashed N Herqash
Journal:  Molecules       Date:  2020-09-07       Impact factor: 4.411

4.  Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma.

Authors:  Ibrahim A Darwish; Nourh Z Alzoman; Reem M Abuhejail; Tilal E El-Samani
Journal:  Chem Cent J       Date:  2012-10-26       Impact factor: 4.215

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.